Belimumab is designed to treat SLE by targeting and inhibiting specific proteins involved in the disease’s progression, thereby reducing disease activity and improving patient quality of life.

Adding a single cycle of rituximab to belimumab (Benlysta) did not improve disease control for patients with systemic lupus erythematosus (SLE) in comparison with belimumab alone in a phase 3 ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus (SLE) when added to standard therapy, according to study results ...

Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.

Patients with non-renal SLE who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.

A new study finds that belimumab (Benlysta®) is an effective therapy option for people with cutaneous lupus erythematosus (CLE), a form of lupus that affects the skin. This study highlights that ...

A 2-year randomized controlled trial has found that belimumab plus standard therapy is superior to standard therapy alone in patients with lupus nephritis, according to data published in the New ...

When to Use Belimumab Where I do see this drug being used is in those patients with moderately severe disease, with symptoms such as more severe arthritis, serositis, fever, fatigue, and skin rash.

Joan T Merrill, MD, from the Oklahoma Medical Research Foundation in Oklahoma City, and colleagues evaluated the long-term safety profile of belimumab for SLE. Patients were randomized to receive ...

Belimumab (Benlysta) generic is a monoclonal antibody, prescribed for active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.

The authors said belimumab did not spark statistically significant benefits either in terms of reducing relapses (1.4 in the 6 months on therapy vs 2.0 in the 6 months before therapy; P = .21) or ...

Belimumab (trade name Benlysta) has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). This monoclonal antibody ...